Yudai Fujimoto

Yudai Fujimoto

Auto-generated profile, based on publicly available information

Yudai Fujimoto

Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Japan

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
DMDaichi Maeda
Daichi Maeda
YFYudai Fujimoto
Yudai Fujimoto
TNTaisuke Nakade
Taisuke Nakade
TATakuro Abe
Takuro Abe
SIShiro Ishihara
Shiro Ishihara
YMYuya Matsue
Yuya Matsue
Maeda D, et al. Korean Circ J. 2024 Apr;54:e51. https://doi.org/10.4070/kcj.2024.0089

1 May 2024 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
KOKoichi Ohashi
Koichi Ohashi
YMYuya Matsue
Yuya Matsue
DMDaichi Maeda
Daichi Maeda
YFYudai Fujimoto
Yudai Fujimoto
NKNobuyuki Kagiyama
Nobuyuki Kagiyama
TMTohru Minamino
Tohru Minamino
BACKGROUND: Although frailty is strongly associated with mortality in patients with heart failure (HF), the risk of which specific cause of death is associated with being complicated with frailty is unclear. We aimed to clarify the association between multidomain frailty and the causes of death in elderly patients hospitalized with HF. METHODS: We analyzed data from the FRAGILE-HF cohort, where patients aged 65 years and older, hospitalized with HF, were prospectively registered between 2016 and 2018 in 15 Japanese hospitals before discharge and followed up for 2 years. All patients were assessed for physical, social, and cognitive dysfunction, and categorized into 3 groups based on their number of frailty domains (FDs, 0–1, 2, and 3). Kaplan-Meier survival analysis was used to evaluate the association between the number of FDs and all-cause mortality, whereas Fine-Gray competing risk regression analysis was used for assessing the impact on cause-specific mortality. RESULTS: We analyzed 1181 patients with HF (81 years old in median, 57.4% were male), 530 (44.9%), 437 (37.0%), and 214 (18.1%) of whom were categorized into the FD 0 to 1, FD 2, and FD 3 groups, respectively. During the 2-year follow-up, 240 deaths were observed (99 HF deaths, 34 cardiovascular deaths, and 107 noncardiovascular deaths), and an increase in the number of FD was significantly associated with mortality (Log-rank: P <0.001). The Fine-Gray competing risk analysis adjusted for age and sex showed that FDs 2 (subdistribution hazard ratio, 1.77 [95% CI, 1.11–2.81]) and 3 (2.78, [95% CI, 1.69–4.59]) groups were associated with higher incidence of noncardiovascular death but not with HF and other cardiovascular deaths. CONCLUSIONS: Although multidomain frailty is strongly associated with mortality in older patients with HF, it is mostly attributable to noncardiovascular death and not cardiovascular death, including HF death. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: UMIN000023929

21 May 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
HSHiroshi Saito
Hiroshi Saito
DMDaichi Maeda
Daichi Maeda
NKNobuyuki Kagiyama
Nobuyuki Kagiyama
TSTsutomu Sunayama
Tsutomu Sunayama
TDTaishi Dotare
Taishi Dotare
YMYuya Matsue
Yuya Matsue
Background: Social factors encompass a broad spectrum of nonmedical factors, including objective (social isolation [SI]) and perceived (loneliness) conditions. Although social factors have attracted considerable research attention, information regarding their impact on patients with heart failure is scarce. We aimed to investigate the prognostic impact of objective SI and loneliness in older patients with heart failure. Methods and Results: This study was conducted using the FRAGILE‐HF (Prevalence and Prognostic Value of Physical and Social Frailty in Geriatric Patients Hospitalized for Heart Failure; derivation cohort) and Kitasato cohorts (validation cohort), which included hospitalized patients with heart failure aged ≥65 years. Objective SI and loneliness were defined using the Japanese version of Lubben Social Network Scale‐6 and diagnosed when the total score for objective and perceived questions on the Lubben Social Network Scale‐6 was below the median in the FRAGILE‐HF. The primary outcome was 1‐year death. Overall, 1232 and 405 patients in the FRAGILE‐HF and Kitasato cohorts, respectively, were analyzed. Objective SI and loneliness were observed in 57.8% and 51.4% of patients in the FRAGILE‐HF and 55.4% and 46.2% of those in the Kitasato cohort, respectively. During the 1‐year follow‐up, 149 and 31 patients died in the FRAGILE‐HF and Kitasato cohorts, respectively. Cox proportional hazard analysis revealed that objective SI, but not loneliness, was significantly associated with 1‐year death after adjustment for conventional risk factors in the FRAGILE‐HF. These findings were consistent with the validation cohort. Conclusions: Objective SI assessed using the Lubben Social Network Scale‐6 may be a prognostic indicator in older patients with heart failure. Given the lack of established SI assessment methods in this population, further research is required to refine such methods.

19 March 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
YAYuka Akama
Yuka Akama
YFYudai Fujimoto
Yudai Fujimoto
YMYuya Matsue
Yuya Matsue
DMDaichi Maeda
Daichi Maeda
KYKenji Yoshioka
Kenji Yoshioka
TMTohru Minamino
Tohru Minamino
Background: Current guidelines recommend placing an implantable cardiac defibrillator for patients with cardiac sarcoidosis and a severely impaired left ventricular ejection fraction (LVEF) of ≤35%. In this study, we determined the association between mild or moderate LVEF impairment and fatal ventricular arrhythmic event (FVAE). Methods and Results: We retrospectively analyzed 401 patients with cardiac sarcoidosis without sustained ventricular arrhythmia at diagnosis. The primary end point was an FVAE, defined as the combined endpoint of documented ventricular tachycardia or ventricular fibrillation and sudden cardiac death. Two cutoff points for LVEF were used: a sex‐specific lower threshold of normal range of LVEF (52% for men and 54% for women) and an LVEF of 35%, which is used in the current guidelines. During a median follow‐up of 3.2 years, 58 FVAEs were observed, and the 5‐ and 10‐year estimated incidences of FVAEs were 16.8% and 23.0%, respectively. All patients were classified into 3 groups according to LVEF: impaired LVEF group, mild to moderate impairment of LVEF group, and maintained LVEF group. Multivariable competing risk analysis showed that both the impaired LVEF group (hazard ratio [HR], 3.24 [95% CI, 1.49–7.04]) and the mild to moderate impairment of LVEF group (HR, 2.16 [95% CI, 1.04–4.46]) were associated with a higher incidence of FVAEs than the maintained LVEF group after adjustment for covariates. Conclusions: Patients with cardiac sarcoidosis are at a high risk of FVAEs, regardless of documented ventricular arrhythmia at the time of diagnosis. In patients with cardiac sarcoidosis, mild to moderate impairment of LVEF is associated with FVAEs.

6 January 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
YAYuka Akama
Yuka Akama
TNTaisuke Nakade
Taisuke Nakade
YMYuya Matsue
Yuya Matsue
NKNobuyuki Kagiyama
Nobuyuki Kagiyama
YNYutaka Nakamura
Yutaka Nakamura
TMTohru Minamino
Tohru Minamino
Background: The prognostic value of handgrip strength, a simple and reliable indicator of sarcopenia, in older patients with heart failure remains uncertain. This study aimed to investigate the prognostic value of handgrip strength in hospitalized patients aged ≥65 years with heart failure. Methods: This post hoc analysis used data from FRAGILE‐HF (Prevalence and Prognostic Value of Physical and Social Frailty in Geriatric Patients Hospitalized for Heart Failure), a prospective, multicenter cohort study involving patients aged ≥65 years hospitalized for heart failure. Handgrip strength was measured before discharge using a dynamometer, with the higher value from 2 trials recorded. Measurements were standardized by dividing 28 and 18 kg for men and women, respectively, per 2019 Asian Working Group for Sarcopenia criteria. Patients were categorized into tertiles (tertile 1, highest; tertile 2, middle; and tertile 3, lowest). The primary outcome was 2‐year all‐cause death. Results: Among 1269 patients (median age, 81 years; 57.1% men), 275 died during follow‐up. Kaplan–Meier analysis revealed a stepwise increase in death across the lowest handgrip tertiles, which remained significant after multivariable adjustment (tertile 2 versus tertile 1: hazard ratio [HR], 1.64 [95% CI, 1.14–2.37]; P =0.007; tertile 3 versus tertile 1: HR, 2.03 [95% CI, 1.42–2.90]; P <0.001). The analysis using a linear model showed that the prognostic impact of reduced handgrip strength increased with age. Conclusions: Lower handgrip strength was independently associated with death in older patients with heart failure, with stronger associations observed in the oldest patients. These findings highlight the additional prognostic value of handgrip strength beyond conventional risk factors. Registration: URL: center6.umin.ac.jp ; Unique Identifier: UMIN000023929.

Verified
Journal Article
Open access
PDF file
Andrew XanthopoulosAndrew Xanthopoulos
Andrew Xanthopoulos
ABAngeliki Bourazana
Angeliki Bourazana
YMYuya Matsue
Yuya Matsue
YFYudai Fujimoto
Yudai Fujimoto
SOShogo Oishi
Shogo Oishi
TKTakeshi Kitai
Takeshi Kitai
Patients with heart failure (HF) patients may die either suddenly (sudden cardiac death/SCD) or progressively from pump failure. The heightened risk of SCD in patients with HF may expedite important decisions about medications or devices. We used the Larissa Heart Failure Risk Score (LHFRS), a validated risk model for all-cause mortality and HF rehospitalization, to investigate the mode of death in 1363 patients enrolled in the Registry Focused on Very Early Presentation and Treatment in Emergency Department of Acute Heart Failure (REALITY-AHF). Cumulative incidence curves were generated using a Fine–Gray competing risk regression, with deaths that were not due to the cause of death of interest as a competing risk. Likewise, the Fine–Gray competing risk regression analysis was used to evaluate the association between each variable and the incidence of each cause of death. The AHEAD score, a well-validated HF risk score ranging from 0 to 5 (atrial fibrillation, anemia, age, renal dysfunction, and diabetes mellitus), was used for the risk adjustment. Patients with LHFRS 2–4 exhibited a significantly higher risk of SCD (HR hazard ratio adjusted for AHEAD score 3.15, 95% confidence interval (CI) (1.30–7.65), p = 0.011) and HF death (adjusted HR for AHEAD score 1.48, 95% CI (1.04–2.09), p = 0.03), compared to those with LHFRS 0,1. Regarding cardiovascular death, patients with higher LHFRS had significantly increased risk compared to those with lower LHFRS (HR 1.44 adjusted for AHEAD score, 95% CI (1.09–1.91), p = 0.01). Lastly, patients with higher LHFRS exhibited a similar risk of non-cardiovascular death compared to those with lower LHFRS (HR 1.44 adjusted for AHEAD score, 95% CI (0.95–2.19), p = 0.087). In conclusion, LHFRS was associated independently with the mode of death in a prospective cohort of hospitalized HF patients.